Dafna Capital Management LLC Kura Oncology, Inc. Transaction History

Dafna Capital Management LLC

  • $389 Million
  • Q3 2024

A detailed history of Dafna Capital Management LLC transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Dafna Capital Management LLC holds 408,368 shares of KURA stock, worth $3.7 Million. This represents 2.05% of its overall portfolio holdings.

Number of Shares
408,368
Previous 423,500 3.57%
Holding current value
$3.7 Million
Previous $8.72 Million 8.49%
% of portfolio
2.05%
Previous 2.24%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$18.57 - $23.23 $281,001 - $351,516
-15,132 Reduced 3.57%
408,368 $7.98 Million
Q2 2024

Aug 14, 2024
BUY
$17.53 - $22.98 $189,972 - $249,034
10,837 Added 2.63%
423,500 $8.72 Million
Q1 2024

May 15, 2024
SELL
$13.42 - $23.53 $1.07 Million - $1.88 Million
-80,021 Reduced 16.24%
412,663 $8.8 Million
Q4 2023

Feb 14, 2024
SELL
$7.58 - $14.38 $440,398 - $835,478
-58,100 Reduced 10.55%
492,684 $7.08 Million
Q3 2023

Nov 14, 2023
BUY
$8.44 - $11.86 $1.63 Million - $2.29 Million
193,000 Added 53.94%
550,784 $5.02 Million
Q2 2023

Aug 14, 2023
BUY
$9.62 - $13.99 $2.39 Million - $3.47 Million
248,000 Added 225.9%
357,784 $3.79 Million
Q1 2023

May 15, 2023
SELL
$10.71 - $14.6 $374,850 - $511,000
-35,000 Reduced 24.17%
109,784 $1.34 Million
Q4 2022

Feb 14, 2023
SELL
$11.23 - $16.9 $691,150 - $1.04 Million
-61,545 Reduced 29.83%
144,784 $1.8 Million
Q3 2022

Nov 14, 2022
BUY
$12.01 - $19.45 $1.06 Million - $1.72 Million
88,500 Added 75.11%
206,329 $2.82 Million
Q2 2022

Aug 15, 2022
BUY
$10.71 - $18.33 $48,195 - $82,484
4,500 Added 3.97%
117,829 $2.16 Million
Q1 2022

May 16, 2022
BUY
$11.78 - $16.98 $29,450 - $42,450
2,500 Added 2.26%
113,329 $1.82 Million
Q4 2021

Feb 14, 2022
BUY
$12.22 - $19.57 $122,200 - $195,700
10,000 Added 9.92%
110,829 $1.55 Million
Q3 2021

Nov 15, 2021
BUY
$15.42 - $21.72 $266,766 - $375,756
17,300 Added 20.71%
100,829 $1.89 Million
Q2 2021

Aug 16, 2021
BUY
$20.85 - $29.88 $661,549 - $948,062
31,729 Added 61.25%
83,529 $1.74 Million
Q1 2021

May 17, 2021
BUY
$24.75 - $39.14 $1.06 Million - $1.68 Million
42,800 Added 475.56%
51,800 $1.46 Million
Q4 2020

Feb 16, 2021
SELL
$29.0 - $41.62 $870,551 - $1.25 Million
-30,019 Reduced 76.93%
9,000 $294,000
Q3 2020

Nov 16, 2020
SELL
$16.3 - $30.64 $4.16 Million - $7.82 Million
-255,241 Reduced 86.74%
39,019 $1.2 Million
Q2 2020

Aug 14, 2020
SELL
$7.95 - $18.81 $105,583 - $249,815
-13,281 Reduced 4.32%
294,260 $4.8 Million
Q1 2020

May 15, 2020
BUY
$6.45 - $14.04 $864,725 - $1.88 Million
134,066 Added 77.28%
307,541 $3.06 Million
Q4 2019

Feb 14, 2020
BUY
$12.97 - $15.94 $905,526 - $1.11 Million
69,817 Added 67.35%
173,475 $2.39 Million
Q3 2019

Nov 14, 2019
BUY
$14.75 - $20.87 $832,136 - $1.18 Million
56,416 Added 119.42%
103,658 $1.57 Million
Q2 2019

Aug 14, 2019
BUY
$14.71 - $19.79 $157,161 - $211,436
10,684 Added 29.22%
47,242 $930,000
Q1 2019

May 15, 2019
SELL
$13.73 - $16.87 $1.54 Million - $1.89 Million
-112,059 Reduced 75.4%
36,558 $606,000
Q4 2018

Feb 14, 2019
SELL
$10.6 - $17.49 $973,959 - $1.61 Million
-91,883 Reduced 38.2%
148,617 $2.09 Million
Q3 2018

Nov 14, 2018
BUY
$16.65 - $21.85 $16,650 - $21,850
1,000 Added 0.42%
240,500 $4.21 Million
Q2 2018

Aug 13, 2018
BUY
$14.8 - $18.8 $1.67 Million - $2.12 Million
112,500 Added 88.58%
239,500 $4.36 Million
Q1 2018

May 15, 2018
BUY
$14.5 - $23.4 $140,925 - $227,424
9,719 Added 8.29%
127,000 $2.38 Million
Q4 2017

Feb 14, 2018
BUY
$13.5 - $16.65 $154,197 - $190,176
11,422 Added 10.79%
117,281 $1.79 Million
Q3 2017

Nov 14, 2017
BUY
$6.05 - $14.95 $640,446 - $1.58 Million
105,859
105,859 $1.58 Million

Others Institutions Holding KURA

# of Institutions
188
Shares Held
81.9M
Call Options Held
42.1K
Put Options Held
34K
View Full List

About Kura Oncology, Inc.

KURA Quotes by TradingView
  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $605M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Dafna Capital Management LLC Portfolio

Follow Dafna Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dafna Capital Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email